{"Title":"Zymeworks","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"135","Founded":"","Address":"","Phone":"(604) 678-1388","Web_address":"https://www.zymeworks.com","Market_cup":"$324.0mil","Revenues":"$11.0 mil (last 12 months)","Net_income":"$-33.8 mil (last 12 months)","Symbol":"ZYME","Exchange":"NYSE","Shares":"4.5","Price_range":"$13.00 - $13.00","Est_volume":"$58.5 mil","Manager":"Citigroup/ Barclays/ Wells Fargo Securities/ Canaccord Genuity","CO_managers":"Cormark Securities","Exp_to_trade":"4/28/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"Zymeworks is an innovative, clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Our suite of complementary therapeutic platforms and our fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. These capabilities have resulted in multiple wholly-owned product candidates with the potential to drive superior outcomes in large underserved and unaddressed patient populations, as further described below."}